Oncostatin M protects against demyelination by inducing a protective microglial phenotype

GLIA

Volumn 63, Issue 10, 2015, Pages 1729-1737

  Janssens, Kris ^a   Maheshwari, Anurag ^a   Van den Haute, Chris ^b,c   Baekelandt, Veerle ^b   Stinissen, Piet ^a   Hendriks, Jerome J A ^a   Slaets, Helena ^a   Hellings, Niels ^a  

^a HASSELT UNIVERSITY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c KU LEUVEN UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Demyelination; Microglia; Multiple sclerosis; Oncostatin M

Indexed keywords

INTERLEUKIN 4; ONCOSTATIN M; ONCOSTATIN M RECEPTOR; ACTIN BINDING PROTEIN; AIF1 PROTEIN, MOUSE; CALCIUM BINDING PROTEIN; CHELATING AGENT; CUPRIZONE; CYTOKINE; GLIAL FIBRILLARY ACIDIC PROTEIN; GROWTH INHIBITOR; ONCOSTATIN M RECEPTOR BETA; OSMR PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BONE MARROW CELL; CELL POLARITY; CONTROLLED STUDY; DEMYELINATION; GENE OVEREXPRESSION; IN VIVO STUDY; MACROPHAGE; MICROGLIA; MOUSE; NEUROPROTECTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; ANIMAL; C57BL MOUSE; CENTRAL NERVOUS SYSTEM; CHEMICALLY INDUCED; DEMYELINATING DISEASES; DISEASE MODEL; DRUG EFFECTS; GENETIC TRANSDUCTION; GENETICS; KNOCKOUT MOUSE; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; TIME FACTOR; UPREGULATION;

ANIMALS; CALCIUM-BINDING PROTEINS; CENTRAL NERVOUS SYSTEM; CHELATING AGENTS; CUPRIZONE; CYTOKINES; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; GLIAL FIBRILLARY ACIDIC PROTEIN; GROWTH INHIBITORS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROFILAMENT PROTEINS; MICROGLIA; ONCOSTATIN M; ONCOSTATIN M RECEPTOR BETA SUBUNIT; PHENOTYPE; TIME FACTORS; TRANSDUCTION, GENETIC; UP-REGULATION;

EID: 84938998638     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.22840     Document Type: Article

References (30)

1. Baekelandt V, Claeys A, Eggermont K, Lauwers E, De Strooper B, Nuttin B, Debyser Z. 2002. Characterization of lentiviral vector-mediated gene transfer in adult mouse brain. Hum Gene Ther 13:841-853.
2. Baker BJ, Park KW, Qin H, Ma X, Benveniste EN. 2010. IL-27 inhibits OSM-mediated TNF-alpha and iNOS gene expression in microglia. Glia 58:1082-1093.
3. Broux B, Stinissen P, Hellings N. 2013. Which immune cells matter? The immunopathogenesis of multiple sclerosis. Crit Rev Immunol 33:283-306.
4. Cao L, He C. 2013. Polarization of macrophages and microglia in inflammatory demyelination. Neurosci Bull 29:189-198.
5. Glezer I, Rivest S. 2010. Oncostatin M is a novel glucocorticoid-dependent neuroinflammatory factor that enhances oligodendrocyte precursor cell activity in demyelinated sites. Brain Behav Immun 24:695-704.
6. Hibbits N, Yoshino J, Le TQ, Armstrong RC. 2012. Astrogliosis during acute and chronic cuprizone demyelination and implications for remyelination. ASN Neurol 4:393-408.
7. Hsu MP, Frausto R, Rose-John S, Campbell IL. 2014. Analysis of IL-6/gp130 family receptor expression reveals that in contrast to astroglia, microglia lack the oncostatin M receptor and functional responses to oncostatin M. Glia 63:132-141.
8. Hu X, Leak RK, Shi Y, Suenaga J, Gao Y, Zheng P, Chen J. 2014. Microglial and macrophage polarization-new prospects for brain repair. Nat Rev Neurol 11:56-64.
9. Hulshof S, Montagne L, De Groot CJ, Van Der Valk P. 2002. Cellular localization and expression patterns of interleukin-10, interleukin-4, and their receptors in multiple sclerosis lesions. Glia 38:24-35.
10. Ichihara M, Hara T, Kim H, Murate T, Miyajima A. 1997. Oncostatin M and leukemia inhibitory factor do not use the same functional receptor in mice. Blood 90:165-173.
11. Komori T, Tanaka M, Senba E, Miyajima A, Morikawa Y. 2013. Lack of oncostatin M receptor beta leads to adipose tissue inflammation and insulin resistance by switching macrophage phenotype. J Biol Chem 288:21861-21875.
12. Lindberg RA, Juan TS, Welcher AA, Sun Y, Cupples R, Guthrie B, Fletcher FA. 1998. Cloning and characterization of a specific receptor for mouse oncostatin M. Mol Cell Biol 18:3357-3367.
13. Louis JC, Magal E, Takayama S, Varon S. 1993. CNTF protection of oligodendrocytes against natural and tumor necrosis factor-induced death. Science 259:689-692.
14. Moidunny S, Dias RB, Wesseling E, Sekino Y, Boddeke HW, Sebastiao AM, Biber K. 2010. Interleukin-6-type cytokines in neuroprotection and neuromodulation: Oncostatin M, but not leukemia inhibitory factor, requires neuronal adenosine a1 receptor function. J Neurochem 114:1667-1677.
15. Murray PJ, Wynn TA. 2011. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 11:723-737.
16. Nakamura K, Nonaka H, Saito H, Tanaka M, Miyajima A. 2004. Hepatocyte proliferation and tissue remodeling is impaired after liver injury in oncostatin M receptor knockout mice. Hepatology 39:635-644.
17. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. 2000. Multiple sclerosis. N Engl J Med 343:938-952.
18. Pereira GB, Dobretsova A, Hamdan H, Wight PA. 2011. Expression of myelin genes: Comparative analysis of Oli-neu and n20.1 oligodendroglial cell lines. J Neurosci Res 89:1070-1078.
19. Ponomarev ED, Maresz K, Tan Y, Dittel BN. 2007. CNS-derived interleukin-4 is essential for the regulation of autoimmune inflammation and induces a state of alternative activation in microglial cells. J Neurosci 27:10714-10721.
20. Ruprecht K, Kuhlmann T, Seif F, Hummel V, Kruse N, Bruck W, Rieckmann P. 2001. Effects of oncostatin M on human cerebral endothelial cells and expression in inflammatory brain lesions. J Neuropathol Exp Neurol 60:1087-1098.
21. Slaets H, Dumont D, Vanderlocht J, Noben JP, Leprince P, Robben J, Hendriks J, Stinissen P, Hellings N. 2008. Leukemia inhibitory factor induces an antiapoptotic response in oligodendrocytes through Akt-phosphorylation and up-regulation of 14-3-3. Proteomics 8:1237-1247.
22. Slaets H, Hendriks JJ, Van den Haute C, Coun F, Baekelandt V, Stinissen P, Hellings N. 2010. CNS-targeted LIF expression improves therapeutic efficacy and limits autoimmune-mediated demyelination in a model of multiple sclerosis. Mol Ther 18:684-691.
23. Slaets H, Nelissen S, Janssens K, Vidal PM, Lemmens E, Stinissen P, Hendrix S, Hellings N. 2014. Oncostatin M reduces lesion size and promotes functional recovery and neurite outgrowth after spinal cord injury. Mol Neurobiol 50:1142-1151.
24. Tanaka M, Hirabayashi Y, Sekiguchi T, Inoue T, Katsuki M, Miyajima A. 2003. Targeted disruption of oncostatin M receptor results in altered hematopoiesis. Blood 102:3154-3162.
25. Tripathi C, Tewari BN, Kanchan RK, Baghel KS, Nautiyal N, Shrivastava R, Kaur H, Bhatt ML, Bhadauria S. 2014. Macrophages are recruited to hypoxic tumor areas and acquire a Pro-Angiogenic M2-Polarized phenotype via hypoxic cancer cell derived cytokines Oncostatin M and Eotaxin. Oncotarget 5:5350-5368.
26. Van Wagoner NJ, Choi C, Repovic P, Benveniste EN. 2000. Oncostatin M regulation of interleukin-6 expression in astrocytes: Biphasic regulation involving the mitogen-activated protein kinases erk1/2 and p38. J Neurochem 75:563-575.
27. Voss EV, Skuljec J, Gudi V, Skripuletz T, Pul R, Trebst C, Stangel M. 2012. Characterisation of microglia during de- and remyelination: Can they create a repair promoting environment?. Neurobiol Dis 45:519-528.
28. Weiss TW, Samson AL, Niego B, Daniel PB, Medcalf RL. 2006. Oncostatin M is a neuroprotective cytokine that inhibits excitotoxic injury in vitro and in vivo. FASEB J 20:2369-2371.
29. Williams A, Piaton G, Lubetzki C. 2007. Astrocytes-friends or foes in multiple sclerosis? Glia 55:1300-1312.
30. Zhang Y, Taveggia C, Melendez-Vasquez C, Einheber S, Raine CS, Salzer JL, Brosnan CF, John GR. 2006. Interleukin-11 potentiates oligodendrocyte survival and maturation, and myelin formation. J Neurosci 26:12174-12185.